Bioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patients

"First Antiviral Drug in Glycovirology"

BOSTON, MASSACHUSETTS - September 6, 2023 - BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), to initiate clinical trials of ProLectin-M for the treatment of mild to moderate COVID-19 in standard risk patients.

“This clearance of ProLectin-M into the clinic is very important given that this is the first of a number of indications that we intend to pursue to treat large unmet medical needs with our Glycovirology technology,” said Dr Leslie Ajayi, Bioxytran Chief Medical Officer. “This is an important milestone for our Company, as it represents our first program to receive FDA clearance to enter the clinic and paves the way for us to pursue other viral indications.

This class of galectin inhibitors is groundbreaking because peer reviewed clinical trial results suggest many patients can become PCR negative in as little as 3 days. Even though we are seeing a resurgence of COVID-19 and its newest variants, BA.2.86 and EG.5, we view our COVID-19 trials as case studies designed to showcase the potential of the galectin antagonist as a broad-spectrum antiviral drug.”

About ProLectin-M

ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responders rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responders rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval.

About Bioxytran, Inc.

Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment.

More information can be found at www.bioxytraninc.com

Media Contact
Company Name: Bioxytran, Inc.
Contact Person: Investor Relations
Email: Send Email
Phone: 617.510.2539
Country: United States
Website: https://www.bioxytraninc.com/

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Bioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patients